Amicus Therapeutics, Inc.(FOLD)NASDAQ
Stock Overview & Analysis
Amicus Therapeutics, Inc. (FOLD) quick overview 2026-02-20
- The stock is currently trading at $14.34, experiencing a price strength within a larger uptrend—trading above its 50-day average while holding above the 200-day.
- Analysts appear optimistic, with a 1-year price target of $14.50 (1.1% upside).
- Volatility is elevated (2.15% annualized), implying wide price swings.
- The fundamental story is nuanced: solid revenue growth (19.50% YoY) alongside significant competitive pressures.
Here's What You Need to Know Right Now
Concise, actionable context
Amicus Therapeutics, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $4.60B
P/E Ratio
Forward P/E: 22.18
Revenue Growth
Year over Year
Analyst Target
+1.1% upside potential
Key Investor Questions
Clarity over jargon
- Technicals say: Neutral (RSI 68.96)
- Fundamentals say: Caution warranted (high leverage concerns)
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
- $442.82M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
Trading Range
Over the past year, the stock traded between $5.51 and $14.38—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility
With 2.15% annualized volatility and β=0.43, the stock exhibits low sensitivity to market moves—suitable for investors comfortable with active risk management.
Ownership Snapshot
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment
Latest News
Recent headlines and coverage
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections
Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the 13 hot stocks to buy with the highest upside potential. On January 27, TD Cowen analyst Ritu Baral maintained the firm’s Hold rating on Amicus Therapeutics Inc. (NASDAQ:FOLD), as well as the $14.50 price target on the stock. Amicus’s pre-announced fourth-quarter and full-year 2025 total product revenue […]
BioMarin Debt Deal And VOXZOGO Approval Recast Rare Disease Outlook
BioMarin Pharmaceutical (NasdaqGS:BMRN) has closed a large debt offering to help fund its pending acquisition of Amicus Therapeutics. The company has also received Health Canada approval for VOXZOGO as a treatment for achondroplasia, extending access to patients in Canada. These developments come as BioMarin's shares trade around $59.87. For BioMarin Pharmaceutical (NasdaqGS:BMRN), these updates come at a time when the stock has had mixed returns across timeframes. The share price is around...
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings?
FOLD heads into Q4 earnings with Galafold driving growth and Pombiliti + Opfolda aiding the top line. BioMarin is set to acquire the company for $4.8 billion.
Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments
If you are wondering whether Amicus Therapeutics at around US$14.30 is attractively priced or already reflecting a lot of optimism, this article walks you through what the numbers are actually saying about value. The stock has been fairly steady over the past week and month at around 0.1% returns. The 1 year return of 48.2% and multi year returns of 13.7% over 3 years and 13.8% over 5 years give important context for where expectations may sit today. Recent coverage around Amicus has focused...
Assessing Amicus Therapeutics (FOLD) Valuation After Strong 3 Month And 1 Year Shareholder Returns
Event context and recent stock performance Amicus Therapeutics (FOLD) has drawn fresh attention after a recent move in its share price, with the stock’s return over the past 3 months sitting near 59% and about 48% over the past year. See our latest analysis for Amicus Therapeutics. With the share price now at $14.30, Amicus Therapeutics has seen its shorter term share price moves stay relatively muted. At the same time, its 3 month share price return of about 59% and 1 year total shareholder...
Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Best Cheap Stocks to Buy Right Now. Barclays initiated coverage of BioMarin on January 28, assigning it an “Overweight” rating and a target price of $80. This target price implies a 41.5% upside from the current price. The firm’s analyst notes that the company’s acquisition plans and “strong […]
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Amicus Therapeutics, Inc. tops our list for being one of the best biotech stocks. TheFly reported on January 22 that Jefferies downgraded FOLD to Buy from Hold and lowered the price target to $14.50 from $16. The company got substantial pharmaceutical […]
BioMarin’s Amicus Deal Funding Reshapes Debt Load And Rare Disease Reach
BioMarin Pharmaceutical (NasdaqGS:BMRN) announced a major debt financing package to support its pending acquisition of Amicus Therapeutics. The company plans to offer US$850 million in senior unsecured notes alongside new term loan facilities. Proceeds are intended to fund the acquisition and related costs, with the transaction expected to reshape BioMarin's capital structure and rare disease portfolio. BioMarin focuses on therapies for rare genetic conditions, a corner of biopharma where...
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?
Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.
Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN) is one of the best large cap stocks under $100 with huge upside potential. On January 20, Canaccord Genuity analyst Whitney Ijem revised her Hold rating on BioMarin Pharmaceutical (NASDAQ:BMRN) to Buy. She also raised her price target estimate from $84 to $98, offering an upside of almost 75% from the prevailing […]
Frequently Asked Questions
Common investor questions about Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. (FOLD) is currently trading at $14.34. The RSI (14-day) is at 69.0, indicating neutral territory. Wall Street analysts have a consensus "Hold" recommendation. The mean analyst price target of $14.50 implies 1.1% upside from current levels. Volatility is low at 2.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Amicus Therapeutics, Inc. (FOLD): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is 22.18. Price-to-Book is 19.20. Price-to-Sales is 7.52. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 5 analysts covering FOLD, the consensus price target is $14.50. This represents a 1.1% upside from the current price of $14.34. The range spans from a low target of $14.50 to a high target of $14.50, reflecting varying levels of optimism among analysts. The consensus recommendation is "Hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Amicus Therapeutics, Inc. (FOLD) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Amicus Therapeutics, Inc. (FOLD) investors include: 1. Elevated debt levels (D/E ratio of 192.18) which could pressure margins in a rising rate environment. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Amicus Therapeutics, Inc.'s (FOLD) current debt and financial health profile: Total debt stands at $442.82M. The debt-to-equity ratio is 192.18, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 2.99, indicating strong short-term liquidity. The quick ratio is 1.90. The company holds $263.84M in cash and equivalents. Free cash flow is positive at $38.40M, providing a cushion for debt servicing and shareholder returns.